<DOC>
	<DOCNO>NCT01902290</DOCNO>
	<brief_summary>The purpose study determine brodalumab ( AMG 827 ) safe effective compare placebo measure change Asthma Control Questionnaire ( ACQ ) composite score .</brief_summary>
	<brief_title>Study Efficacy Safety Brodalumab Compared With Placebo Inadequately Controlled Asthma Subjects With High Bronchodilator Reversibility</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Bronchodilator Agents</mesh_term>
	<criteria>Diagnosis asthma , presently reversibility prebronchodilator FEV1 ≥ 20 % screen Percent predict FEV1 ≥ 40 % ≤ 80 % screen ICS ≥ 200 ≤ 1000/μg/day fluticasone powder equivalent Ongoing asthma symptom ACQ composite score screen baseline ≥ 1.5 point History chronic obstructive pulmonary disease chronic pulmonary condition asthma History allergic bronchopulmonary aspergillosis Respiratory infection within 4 week screen 1 week baseline visit Subject know history Crohn 's disease Subject significant concurrent medical condition laboratory abnormality , define study protocol Subject previously use antiIL17 biologic therapy Subject pregnant breastfeeding , plan become pregnant enrol study Female subject unwilling use highly effective method birth control unless 2 year postmenopausal surgically sterile Subject severe depression measure Personal Health Questionnaire Depression Scale ( PHQ8 ) suicidal ideation/behavior measure Columbia Suicide Severity Rating Scale ( eCSSRS ) Subject history evidence psychiatric disorder substance abuse consider Investigator pose risk subject safety</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Inadequately control asthma , brodalumab , AMG 827</keyword>
</DOC>